Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults
Chemotherapy Research and Practice · 2011
DOI: 10.1155/2011/393976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy Research and Practice, 2011. Verfasst von Pauline Byakika-Kibwika und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Medical Research Council, Infectious Diseases Network for Treatment and Research in Africa, University Of Liverpool.
Abstract (Originalsprache)
Background
We aimed to assess cardiac conduction safety of coadministration of the CYP3A4 inhibitor lopinavir/ritonavir (LPV/r) and the CYP3A4 substrate artemether-lumefantrine (AL) in HIV-positive Ugandans.
Methods
Open-label safety study of HIV-positive adults administered single-dose AL (80/400 mg) alone or with LPV/r (400/100 mg). Cardiac function was monitored using continuous electrocardiograph (ECG).
Results
Thirty-two patients were enrolled; 16 taking LPV/r -based ART and 16 ART naïve. All took single dose AL. No serious adverse events were observed. ECG parameters in milliseconds remained within normal limits. QTc measurements did not change significantly over 72 hours although were higher in LPV/r arm at 24 (424 versus 406; P = .02 ) and 72 hours (424 versus 408; P = .004 ) after AL intake.
Conclusion
Coadministration of single dose of AL with LPV/r was safe; however, safety of six-dose AL regimen with LPV/r should be investigated.
Autor:innen und Institutionen
- Infectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda.
Förderung
- Medical Research Council
- Infectious Diseases Network for Treatment and Research in Africa
- University Of Liverpool
Zitieren
APA
Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., Boffito, M., Katabira, E., Back, D., Khoo, S., & Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice. https://doi.org/10.1155/2011/393976
Vancouver
Byakika-Kibwika P, Lamorde M, Lwabi P, Nyakoojo WB, Okaba-Kayom V, Mayanja-Kizza H, et al. Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice. 2011. doi:10.1155/2011/393976
BibTeX
@article{ByakikaKibwika2011,
author = {Byakika-Kibwika, Pauline and Lamorde, Mohammed and Lwabi, Peter and Nyakoojo, Wilson B and Okaba-Kayom, Violet and Mayanja-Kizza, Harriet and Boffito, Marta and Katabira, Elly and Back, David and Khoo, Saye and Merry, Concepta},
title = {Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults},
journal = {Chemotherapy Research and Practice},
year = {2011},
doi = {10.1155/2011/393976}
}
EUVIMED